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This study aimed to assess the effect of BiPAP®, by nasal mask, on exercise tolerance and respiratory
muscle strength in patients with a clinical and spirometric diagnosis of moderate/severe COPD (FEV1 < 60% of
predicted). Ten patients of 59.4±8.9 years old, with FEV1/FVC <70% of predicted level, were treated with 30
minutes of BiPAP® (IPAP:10 and 15 cmH2O; EPAP:4 cmH2O), three days per week, during two months. Before
and after the treatment, spirometry, inspiratory (MIP) and expiratory (MEP) muscle strength and the distance
walked in six minutes (6MWT) were measured. We observed a significant increase (Wilcoxon, p<0.05) in the
mean values of MIP (from -55±17 to -77±19, respectively), MEP (from 75±20 to 109±36, respectively) and
walking distance (from 349±67 to 448±75). Based on these results, we concluded that BiPAP® improves
respiratory muscle strength and exercise tolerance in these COPD patients.
DESCRIPTORS: pulmonary disease, chronic obstructive; pulmonary ventilation; exercise tolerance
INFLUENCIA DE LA VENTILACIÓN NO EVASIVA MEDIANTE EL BIPAP® SOBRE
LA TOLERANCIA AL EJERCICIO FÍSICO Y FUERZA MUSCULAR RESPIRATORIA
EN PACIENTES CON ENFERMEDAD PULMONAR OBSTRUTIVA CRÓNICA (EPOC)
El objetivo de esto estudio fue evaluar el efecto del BiPAP®, por medio de la máscara nasal, sobre la
tolerancia al ejercicio físico y el desempeño muscular respiratorio en pacientes con diagnosis clínico y
espirométrico de EPOC moderada/grave (VEF1 < 60% del previsible). Con VEF1/CVF <70% del previsible y
edad promedia de 59,4±8,9 años, diez pacientes fueron tratados con 30 minutos de BiPAP® (IPAP=10-15 e
EPAP=4 cmH2O), en tres sesiones semanales, durante dos meses. Antes y después del tratamiento, fue medida
la espirometría, la fuerza muscular inspiratoria (PImax) y expiratoria (PEmax) y la distancia cubierta en seis
minutos (TC6). Fueron evidenciados aumentos significativos (Wilcoxon, p<0,05) en el promedio de la PImax
(de -55±17 a -77±19 cmH2O), de la PEmax (de 75±20 a 109±36 cmH2O) y de la distancia cubierta (de 349±67
a 447±75 metros). Con base en estos resultados, se concluye que el BiPAP® mejoró el desempeño muscular
respiratorio y la tolerancia al ejercicio físico en estos pacientes con EPOC.
DESCRIPTORES: enfermedad pulmonar obstructiva crónica; ventilación pulmonar; tolerancia al ejercicio
INFLUÊNCIA DA VENTILAÇÃO NÃO INVASIVA POR MEIO DO BIPAP® SOBRE
A TOLERÂNCIA AO EXERCÍCIO FÍSICO E FORÇA MUSCULAR RESPIRATÓRIA
EM PACIENTES COM DOENÇA PULMONAR OBSTRUTIVA CRÔNICA (DPOC)
O objetivo deste estudo foi avaliar o efeito do BiPAP®, através de máscara nasal, na tolerância ao
exercício físico e no desempenho muscular respiratório em pacientes com diagnóstico clínico e espirométrico
de DPOC, moderado/grave (VEF1 < 60% do previsto). Com VEF1/CVF <70% do previsto e idade média de
59,4±8,9 anos, dez pacientes com doença pulmonar obstrutiva crônica (DPOC) foram tratados com 30 minutos
de BiPAP® (IPAP=10-15 e EPAP=4 cmH2O), em três sessões semanais, durante dois meses. Antes e após o
tratamento mediu-se a espirometria, a força muscular inspiratória (PImax) e expiratória (PEmax) e a distância
percorrida em seis minutos (TC6). Foram constatados aumentos significativos (Wilcoxon, p<0,05) na média da
PImax (de -55±17 para -77±19 cmH2O), da PEmax (de 75±20 para 109±36 cmH2O) e da distância percorrida
(de 349±67 para 448±75 metros). Com base nesses resultados conclui-se que o BiPAP® melhorou o desempenho
muscular respiratório e a tolerância ao exercício físico nesses pacientes com DPOC.
DESCRITORES: doença pulmonar obstrutiva crônica; ventilação pulmonar; tolerância ao exercício
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INTRODUCTION
Noninvasive ventilation (NIV) has been used
successfully for treating respiratory insufficiency due
to different causes, including sleep apnea, chronic
obstructive pulmonary disease (COPD) and pulmonary
edema(1). The application of bi-level positive airway
pressure (BiPAP®), which associates the pressure of
ventilatory support with positive final pressure, aims
to increase alveolar recruitment during inspiration and
prevent alveolar collapse during expiration(2).
Some studies(3) have attempted to analyze
the influence of BiPAP® on the respiratory muscles
and exercise tolerance in patients with COPD. Their
results showed that patients who are treated with
BiPAP® two hours per day, during five consecutive
days, present greater respiratory muscle rest,
improved tolerance and reduced dyspnea. Similar
results have been found in other studies(4), which
attributed the increase in respiratory muscle strength
to the muscle rest promoted by NIV. However, other
research(5) has not demonstrated any significant
growth in respiratory muscle strength.
As COPD patients present ventilatory
limitations that lead to progressive intolerance to
efforts(6), due to dyspnea, weakness and
deconditioning of respiratory and peripheral
muscles(7), making them vulnerable to hospitalization,
this study aims to assess the effects of bi-level NIV in
COPD patients on exercise tolerance and respiratory
muscle strength.
MATERIALS AND METHODS
Individuals: We studied ten individuals, five
men and five women, with a mean age of 65.3±9.6
years, ex-smokers, whose physicians had prescribed
pulmonary rehabilitation at the Special Unit for
Respiratory Physiotherapy, with a clinical and
spirometric diagnosis of moderate/severe COPD (FEV1
<60% of predicted), with FEV1/FVC <70% of
predicted, and clinically stable. These patients, who
were receiving bronchodilators (berotec and/or
atrovent) for cases of intense dyspnea, were
submitted to a general and specific evaluation of the
respiratory system and signed a consent term to
participate in the proposed program, as recommended
by Brazilian legislation for research involving human
beings. This study was approved by the ethics
committee for research involving human beings at
the institution where the study was carried out.
Inclusion criteria were the absence of
associated cardiovascular diseases, orthopedic
diseases, hyperresponsiveness and neuromuscular
disorders that would impede the realization of
experimental procedures proposed in this study.
Experimental procedure: Before and after
treatment, patients were submitted to the following
assessments:
- Spirometry: carried out by means of a Vitalograph
spirometer, model 2021, according to American
Thoracic Society(8) standards, to characterize the
degree of obstructive pulmonary disorder.
- Respiratory Muscle Strength: obtained by using a
Ger-Ar mano-vacuummeter scaled in cmH2O.
Maximum inspiratory pressure (MIP) and maximum
expiratory pressure (MEP) were measured according
to earlier studies(9), with the individual in the orthostatic
position and with a nose clip. MIP was measured close
to the residual volume after maximum expiration. MEP
was measured close to total pulmonary capacity (TPC)
after maximum inspiration. Individuals were oriented
to sustain pressure for more than a second and each
maneuver was realized at least three times. For the
sake of analysis, the highest result was taken into
account;
- Six-Minute Walking Test (6MWT): to evaluate
exercise tolerance, patients were submitted to a 6MWT
in a flat level corridor of 30 meters length and 1.5
meters width, demarcated every 2 meters.
Patients were advised to take a light meal
about two hours before the test and not to perform
any intense physical exercise, nor take medication
during the 24 hours before the examination, besides
using comfortable clothing and shoes for taking the
test.
Vital signs were measured before and at the
end of the test:
- Systolic (SBP) and diastolic blood pressure (DBP),
using a Diasist stethoscope and BD
sphygmomanometer, through indirect auscultation;
- Cardiac frequency (CF) and peripheral oxygen
saturation (SpO2), using a Nonin 8500A portable pulse
oximeter;
- subjective feeling of dyspnea, using Borg’s perceived
exertion scale, ranging from “zero” for no lack of air
to “ten” for a maximum feeling of lack of air.
The six-minute walking test involved a walk
during which the patient was asked to walk the longest
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possible distance, during a six-month period, receiving
a standardized encouragement every minute(10).
Patients were accompanied by the evaluator during
the six minutes and continuously monitoring through
the pulse oximeter. For the sake of analysis, CF, SpO2
and subjective feeling of dyspnea were recorded
before and after the test. With a view to minimizing
learning effects, each patient carried out two tests
before the treatment, and the longest distance was
calculated.
Noninvasive Ventilation (NIV)
Patients were submitted to NIV by means of
BiPAP®, using a nasal mask, for 30 minutes, three
times per week, on alternate days, during six weeks.
BiPAP® levels were adjusted according to each
patient’s tolerance. Patients remained comfortably
seated throughout the NIV application (with IPAP set
between 10 and 15 cmH2O and EPAP at 4 cmH2O),
and were asked to adopt diaphragmatic breathing (11)
during the application.
STATISTICAL ANALYSIS
For the statistical analysis of physiological
variables and distance walked before and after
treatment with NIV, we used Wilcoxon’s non-
parametrical test, as data did not present a normal
distribution. A p<0.05 significance level was adopted.
RESULTS
Table 1 presents the participants’ individual
anthropometric and demographic characteristics related
to age, gender, weight, height, body mass index (BMI),
with mean values and standard deviations.
Table 1 - Individual anthropometric and demographic
characteristics with mean values and standard
deviations
stcejbuS )sraey(egA redneG )gk(thgieW )m(thgieH )2m/gk(IMB
1 27 M 5.87 36.1 5.92
2 86 M 5.86 66.1 9.42
3 66 M 98 67.1 7.82
4 87 M 5.66 86.1 6.32
5 46 M 27 16.1 8.72
6 46 F 07 56.1 7.52
7 07 F 15 5.1 7.22
8 34 F 901 35.1 6.64
9 36 F 27 25.1 2.13
01 34 F 36 55.1 2.62
DS/naeM 6.9±3.56 7.51±47 1.0±16.1 8.6±7.82
BMI: body mass index; SD: standard deviation.
Table 2 shows the spirometric results
obtained when evaluating and reevaluating patients
who received BiPAP® application. No significant
changes were found between the spirometric indices
obtained before and after NIV treatment.
Table 2 - Spirometric measurements in liters and
percentages of predicted before and after
BiPAP®treatment
FVC: forced vital capacity; FEV1: forced expiratory volume in one second;
MVV: maximum voluntary ventilation; FEF25-75%: forced expiratory flow 25-
75; NS: not significant.
Table 3 presents the mean results for the
following physiological answers: CF, SpO2, subjective
feeling of dyspnea, MIP and MEP, as well as the
distance walked during the 6MWT. We did not find
statistically significant differences between the pre-
and post-treatment situations for CF, SpO2 and
subjective feeling of dyspnea. However, differences
for distance walked, MIP and MEP were statistically
significant.
Table 3 - Comparison between mean values on
dyspnea scale for 6MWT, MIP, MEP and distance
walked, before and after treatment with BiPAP®
SpO2: peripheral oxygen saturation; CF: cardiac frequency; MIP: maximum
inspiratory pressure; MEP: maximum expiratory pressure.
Figure 1 illustrates individual results for
distance walked in meters, obtained before and after
treatment with NIV.
PAPiB-erP ® PAPiB-tsoP ®
)%(CVF 89.11±89.06 67.11±53.75 )SN(
)l(CVF 65.0±87.1 55.0±56.1 )SN(
VEF 1 )%( 29.8±52.34 81.8±90.54
)SN(
VEF 1 )l( 12.0±60.1 82.0±50.1
)SN(
VEF 1 )%(CVF/ 71±4.85 11±8.16
)SN(
)%(VVM 19.8±08.24 17.6±20.44 )SN(
)l(VVM 15.8±38.73 36.01±26.93 )SN(
FEF %57-52 )%( 30.01±25.71 46.9±28.91
)SN(
2FEF %57-5 )l( 82.0±15.0 92.0±85.0
)SN(
®PAPiB-erP ®PAPiB-tsoP eulav-P
OpS 2 )%( 7.3±4.58 6.1±8.29 01.0
)01-0(aenpsyD 5.1±9.2 8.0±7.0 01.0
)mpb(FC 1.01±8.511 1.11±7.711 01.0
Hmc(PIM 2 )O 70.71±05.45- 78.81±66.67- *700.0
Hmc(PEM 2 )O 07±07.47 47.53±44.901 *700.0
)m(deklawecnatsiD 4.76±1.943 92.57±6.744 500.0
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Figure 1 - Individual values for distance walked during
6MWT, obtained during evaluation and reevaluation
DISCUSSION
Noninvasive ventilation has been used in
different studies to provide greater respiratory muscle
rest(4). NIV is able to “alleviate” the inspiratory muscles’
work load, promoting a temporary rest and thus
allowing for better conditions to develop respiratory
muscle strength.
Our results showed that NIV through a nasal
mask by means of BiPAP®, during a six-week period,
significantly increased muscle strength in COPD
patients, in line with literature(12), which has
demonstrated increases in MIP and MEP after the
chronic application of BiPAP® in COPD patients.
Increases in respiratory muscle strength through the
use of pressure support have also been observed(13)
when applying NIV to COPD patients during the night.
Moreover, our results indicated a probable
improvement in exercise tolerance after treatment
with NIV, as we found a significant increase in the
distance walked during the 6MWT which, although very
simple, has been frequently used in field studies(14).
Despite the physical limitations COPD patients
normally present, the distance walked by all of our
patients exceeded 54 meters, as shown in Figure 1.
This has been mentioned(15) as a good indicator of
these patients’ clinical improvement.
Similar results were found in a research(3) that
assessed the effects of BiPAP® when applied for two
hours during the day, for one week. This research
analyzed severe but stable COPD patients, eight of
whom were treated with a placebo method (without
NIV) and seven with BiPAP® two hours per day for
five consecutive days. These authors(3) demonstrated
that BiPAP® improved tolerance and reduced patients’
dyspnea, while the placebo group did not obtain any
significant improvement. However, the study neither
evidenced a clinical improvement nor an increase in
these patients’ respiratory muscle strength(15).
Noninvasive ventilation, as a resource to
improve respiratory muscle strength and physical
performance, may require a longer treatment time,
involving orientations about diaphragmatic
breathing(11). This is characterized as Functional
Respiratory Reeducation. The use of NIV for few days
remains restricted to supporting a rest period for the
respiratory muscles, and does not obligatory entail
changes in COPD patients’ respiratory muscle
strength, nor in their physical condition.
With respect to CF, SpO2 and subjective feeling
of dyspnea, we did not find statistically significant
differences during the 6MWT, when measured after
NIV treatment. These results demonstrate that,
although patients walked a longer distance after the
treatment, these variables remained stable. This
indicates an improvement in the patients’ physical
condition or tolerance, although we could not compare
values for the same effort intensity, which can
normally be controlled during tests carried out on
ergometric equipment, such as a treadmill or bicycle.
Moreover, from a clinical perspective, SpO2 presented
a better saturation range after NIV and perceived
dyspnea, although not significant, showed a downward
tendency.
Although these results are encouraging, some
methodological limitations need to be highlighted, such
as the lack of a control group to provide more solid
support to the efficacy of this alternative and auxiliary
therapeutic technique in the physical training of COPD
patients. Furthermore, our findings reveal the need
for new studies, involving a methodology that can
explore these aspects without ignoring each COPD
patient’s own physical limitations; taking into account
different obstruction levels, using a larger sample and
more complex evaluations, such as ergospirometry
and blood lactate levels.
Finally, we can conclude that, in outpatient
clinics, noninvasive ventilation is an auxiliary technique
for the physical conditioning of COPD patients,
especially with a view to causing a rest for their
respiratory muscles, allowing for greater tolerance
to burdens in respiratory muscle training. This is a
relevant aspect, as these patients present limited
abilities to make physical efforts, weakness and
mechanical alterations in respiratory muscles.
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